Analysts’ Viewpoint
The muscle wasting disorders market size is expected to witness steady growth in the next few years due to an upsurge in the prevalence of muscle wasting disorders, commonly associated with factors such as aging, chronic ailments, neurological issues, and lifestyle choices. With the global population aging and chronic diseases becoming increasingly widespread, the number of individuals impacted by these disorders is steadily mounting, leading to a significant rise in demand for effective treatment solutions.
Extensive research and development initiatives in this field have yielded groundbreaking therapies. These advancements instill fresh optimism among patients, consequently fueling market progress.
The surge in approval of medications by regulatory bodies such as the FDA for treating muscle-wasting disorders is expected to play a crucial role in propelling market growth during the forecast period.
The muscle wasting disorders market, characterized by the progressive degeneration of muscle mass and function, is witnessing significant growth. Ongoing research and development efforts are yielding groundbreaking therapies, encompassing pharmaceuticals, gene-based interventions, and regenerative medicine, offering new and more effective treatment options. Furthermore, the market is anticipated to benefit from heightened awareness regarding muscle wasting disorders and augmented government investments in research and development.
As per the National Center for Biotechnology Information (NCBI), the global prevalence of muscular dystrophy (MD) is estimated to be 16.1 individuals per 100,000 people (equivalent to 1 in 6,200) worldwide. Among MD types, Duchenne muscular dystrophy (DMD) is the most prevalent, with an estimated occurrence rate ranging from 1.7 to 4.2 individuals per 100,000 people. Specifically, DMD is estimated to affect 1 in every 3,500 live male births. A protein called dystrophin, which helps to maintain muscle cells, is altered in Duchenne muscular dystrophy (DMD), a hereditary condition that is characterized by progressive muscle degeneration and weakening. Regulatory approvals, notably from entities such as the FDA, are anticipated to drive market growth by providing a green light to advanced treatments.
Muscle atrophy, another name for muscle wasting syndromes, describes the gradual decrease of muscular mass and strength. A neuromuscular condition known as spinal muscular atrophy (SMA) results in the deterioration and atrophy of muscles. Motor neurons, a particular kind of nerve cell that regulates muscle movement, are found in the spinal cords of people with SMA. In the United States, SMA affects between 10,000 and 25,000 children and adults. About one in every 6,000 to 10,000 kids are affected by this rare condition.
The list of therapeutic treatments for illnesses that cause muscle wasting is expanding and includes medicines, gene therapies, and regenerative medicine techniques. New therapeutic alternatives are provided by these developing medicines, and they may also lead to better patient outcomes, thus offering lucrative opportunities for market expansion.
Additionally, heightened investments in healthcare infrastructure and resources have empowered individuals to access enhanced care for muscle wasting disorders, a significant factor boosting the muscle wasting disorders industry.
Innovative treatments encompass a wide array of approaches. Numerous groundbreaking advancements have emerged in the treatment landscape for muscle wasting disorders, all geared toward the goal of decelerating or reversing muscle depletion, enhancing muscle functionality, and ultimately elevating the overall quality of life for individuals grappling with these conditions. These pioneering developments in addressing muscle wasting disorders hold great promise, offering avenues to significantly enhance outcomes and the well-being of those affected.
One such advancement is Resistance Exercise Training, which entails engaging in exercises requiring muscles to exert force against an external resistance, such as weights or resistance bands. This form of training has demonstrated its capacity to augment muscle mass, bolster strength, and ameliorate function among individuals contending with muscle wasting disorders, often being integrated with other therapeutic strategies for optimal efficacy.
Pharmaceutical interventions represent another notable avenue of progress. Diverse pharmaceutical approaches are under exploration to target muscle-wasting disorders. For instance, there is ongoing investigation into the potential of Selective Androgen Receptor Modulators (SARMs) to amplify muscle mass and strength, while avoiding the side effects linked to conventional anabolic steroids. Additionally, research into myostatin inhibitors and their ability to stimulate muscle growth is underway.
Equally pivotal are innovative nutritional interventions. Appropriate nutrition plays a key role in the management of muscle wasting disorders, and emerging nutritional strategies aim to fine-tune dietary intake to safeguard muscle mass and function. These interventions encompass tailored dietary plans, specialized nutritional supplements, and the inclusion of specific nutrients including essential amino acids, omega-3 fatty acids, and vitamin D to optimize therapeutic outcomes.
The global muscle wasting disorders market segmentation based on type comprises muscular dystrophy and muscular atrophy.
Muscular dystrophy is one of the most familiar and widespread categories of muscle wasting disorders, occupying a prominent position within this classification. Within the realm of muscular dystrophy, Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) emerge as exceptionally well-recognized variants. The prominence of this segment can be attributed to several factors, including its high prevalence, heightened awareness, substantial research emphasis, a multitude of clinical trials and research investigations, and the continuous progress in therapeutic innovations for addressing muscular dystrophy.
Based on treatment type, the market is classified into medications, physical therapy, nutritional therapy, surgery, gene therapy, and others.
Medications have traditionally served as a primary therapeutic avenue for the management of muscle-wasting disorders. Several noteworthy drugs, including ELEVIDYS, EXONDYS 51, VYONDYS 53, AMONDYS 45, SPINRAZA, Zolgensma, Evrysdi, Emflaza, and VILTEPSO, contribute significantly to the sector's revenue.
With continuous progress in drug development, ongoing clinical trials, and dedicated research efforts, the medications segment is poised to maintain its leading position throughout the forecast period. Furthermore, the pharmaceutical industry has made substantial investments in research and development endeavors, aiming to uncover and manufacture innovative medications tailored for the treatment of muscle wasting diseases.
In terms of end-user, the muscle wasting disorders market has been divided into hospitals, rehab centers, specialty clinics, and others. Hospitals have a major market share. Neuromuscular problems are frequently the focus of specialized units and departments in hospitals.
Multidisciplinary care teams with neurologists, physical therapists, and occupational therapists can deliver comprehensive care in these situations. The hospitals segment is projected to be driven by the global increase in hospitals and the enhanced treatment options for illnesses causing muscle wasting that are carried out in these settings. According to the American Hospital Association (AHA), there were 6,093 hospitals in the United States overall in 2022, and that number rose to 6,129 in 2023.
According to the latest muscle wasting disorders market forecast, North America is expected to hold a significant share of the global landscape. High prevalence of various muscle wasting disorders, primarily due to lifestyle factors, an aging population, and increase in chronic diseases is fueling the market dynamics of the region, necessitating a robust healthcare infrastructure and dedicated research efforts to address these conditions.
Moreover, North America boasts a well-established pharmaceutical and biotechnology sector, with a substantial focus on research and development. This emphasis has led to the launch of innovative drugs and therapies for muscle wasting disorders, further propelling market statistics. The presence of key pharmaceutical companies, academic research institutions, and clinical trial centers contributes to the development of cutting-edge treatments and diagnostic tools.
Rise in proportion of elderly population, and augmented government investments in research is anticipated to drive the European market for muscle wasting disorders. Furthermore, the market is poised to benefit from a promising pipeline of new drugs designed to treat muscle wasting disorders. Projections indicate that by 2050, one in four individuals in the region will be aged 65 or older. This demographic shift places a higher susceptibility on individuals to muscle wasting disorders, given that muscle mass and function tend to decline with advancing age.
The escalation of healthcare spending in multiple Asia Pacific nations, encompassing China, Japan, South Korea, and India, has paved the way for enhanced accessibility to advanced therapies for muscle wasting disorders. This surge in investment in healthcare has substantially broadened patient access to superior care, consequently fostering market expansion.
The global muscle wasting disorders market share is fragmented with the presence of a number of players. Emerging players in the muscle wasting disorders market include Biogen, Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Ionis Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., Nippon Shinyaku Co., Ltd. (NS Pharma, Inc.), PTC Therapeutics, Inc., and Teva Pharmaceutical Industries Ltd.
Key players have been profiled in the global muscle wasting disorders market research report based on parameters such as company overview, financial overview, business strategies, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Size in 2022 | US$ 12.7 Bn |
| Forecast Value in 2031 | More than US$ 45.4 Bn |
| CAGR - 2022-2031 | 15.1% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Muscle Wasting Disorders Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
It was valued at US$ 12.7 Bn in 2022
It is projected to reach more than US$ 45.4 Bn by the end of 2031
It is anticipated to be 15.1% from 2023 to 2031
North America is expected to account for the largest share from 2023 to 2031
Biogen, Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Ionis Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., Nippon Shinyaku Co., Ltd. (NS Pharma, Inc.), PTC Therapeutics, Inc., and Teva Pharmaceutical Industries Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Muscle Wasting Disorders Market
4. Market Overview
4.1. Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Global Muscle Wasting Disorders Market Value Analysis and Forecasts, 2017‒2031
5. Key Insights
5.1. Disease Prevalence & Incidence Rate
5.2. Reimbursement Scenario
5.3. Pipeline Analysis
5.4. COVID-19 Pandemic Impact on Industry
6. Global Muscle Wasting Disorders Market Analysis and Forecast, By Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Type, 2017‒2031
6.3.1. Muscular Dystrophy
6.3.1.1. Duchenne Muscular Dystrophy (DMD)
6.3.1.2. Becker Muscular Dystrophy (BMD)
6.3.1.3. Myotonic Muscular Dystrophy
6.3.1.4. Congenital Muscular Dystrophy
6.3.1.5. Limb-Girdle Muscular Dystrophy
6.3.1.6. Others
6.3.2. Muscular Atrophy
6.3.2.1. Physiologic Atrophy
6.3.2.2. Pathologic Atrophy
6.3.2.3. Neurogenic Atrophy
6.4. Market Attractiveness By Type
7. Global Muscle Wasting Disorders Market Analysis and Forecasts, By Treatment Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Treatment Type, 2017‒2031
7.3.1. Medications
7.3.2. Physical Therapy
7.3.2.1. Ultrasound Therapy
7.3.2.2. Electric Simulations
7.3.3. Nutritional Therapy
7.3.4. Surgery
7.3.5. Gene Therapy
7.3.6. Others
7.4. Market Attractiveness By Treatment Type
8. Global Muscle Wasting Disorders Market Analysis and Forecasts, By End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By End-user, 2017‒2031
8.3.1. Hospitals
8.3.2. Rehab Centers
8.3.3. Specialty Clinics
8.3.4. Others
8.4. Market Attractiveness By End-user
9. Global Muscle Wasting Disorders Market Analysis and Forecasts, By Region
9.1. Key Findings
9.2. Market Value Forecast By Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness By Country/Region
10. North America Muscle Wasting Disorders Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Type, 2017‒2031
10.2.1. Muscular Dystrophy
10.2.1.1. Duchenne Muscular Dystrophy (DMD)
10.2.1.2. Becker Muscular Dystrophy (BMD)
10.2.1.3. Myotonic Muscular Dystrophy
10.2.1.4. Congenital Muscular Dystrophy
10.2.1.5. Limb-Girdle Muscular Dystrophy
10.2.1.6. Others
10.2.2. Muscular Atrophy
10.2.2.1. Physiologic Atrophy
10.2.2.2. Pathologic Atrophy
10.2.2.3. Neurogenic Atrophy
10.3. Market Value Forecast By Treatment Type, 2017‒2031
10.3.1. Medications
10.3.2. Physical Therapy
10.3.2.1. Ultrasound Therapy
10.3.2.2. Electric Simulations
10.3.3. Nutritional Therapy
10.3.4. Surgery
10.3.5. Gene Therapy
10.3.6. Others
10.4. Market Value Forecast By End-user, 2017‒2031
10.4.1. Hospitals
10.4.2. Rehab Centers
10.4.3. Specialty Clinics
10.4.4. Others
10.5. Market Value Forecast By Country, 2017‒2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Type
10.6.2. By Treatment Type
10.6.3. By End-user
10.6.4. By Country
11. Europe Muscle Wasting Disorders Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Type, 2017‒2031
11.2.1. Muscular Dystrophy
11.2.1.1. Duchenne Muscular Dystrophy (DMD)
11.2.1.2. Becker Muscular Dystrophy (BMD)
11.2.1.3. Myotonic Muscular Dystrophy
11.2.1.4. Congenital Muscular Dystrophy
11.2.1.5. Limb-Girdle Muscular Dystrophy
11.2.1.6. Others
11.2.2. Muscular Atrophy
11.2.2.1. Physiologic Atrophy
11.2.2.2. Pathologic Atrophy
11.2.2.3. Neurogenic Atrophy
11.3. Market Value Forecast By Treatment Type, 2017‒2031
11.3.1. Medications
11.3.2. Physical Therapy
11.3.2.1. Ultrasound Therapy
11.3.2.2. Electric Simulations
11.3.3. Nutritional Therapy
11.3.4. Surgery
11.3.5. Gene Therapy
11.3.6. Others
11.4. Market Value Forecast By End-user, 2017‒2031
11.4.1. Hospitals
11.4.2. Rehab Centers
11.4.3. Specialty Clinics
11.4.4. Others
11.5. Market Value Forecast By Country/Sub-region, 2017‒2031
11.5.1. U.K.
11.5.2. Germany
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Type
11.6.2. By Treatment Type
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Muscle Wasting Disorders Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Type, 2017‒2031
12.2.1. Muscular Dystrophy
12.2.1.1. Duchenne Muscular Dystrophy (DMD)
12.2.1.2. Becker Muscular Dystrophy (BMD)
12.2.1.3. Myotonic Muscular Dystrophy
12.2.1.4. Congenital Muscular Dystrophy
12.2.1.5. Limb-Girdle Muscular Dystrophy
12.2.1.6. Others
12.2.2. Muscular Atrophy
12.2.2.1. Physiologic Atrophy
12.2.2.2. Pathologic Atrophy
12.2.2.3. Neurogenic Atrophy
12.3. Market Value Forecast By Treatment Type, 2017‒2031
12.3.1. Medications
12.3.2. Physical Therapy
12.3.2.1. Ultrasound Therapy
12.3.2.2. Electric Simulations
12.3.3. Nutritional Therapy
12.3.4. Surgery
12.3.5. Gene Therapy
12.3.6. Others
12.4. Market Value Forecast By End-user, 2017‒2031
12.4.1. Hospitals
12.4.2. Rehab Centers
12.4.3. Specialty Clinics
12.4.4. Others
12.5. Market Value Forecast By Country/Sub-region, 2017‒2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of APAC
12.6. Market Attractiveness Analysis
12.6.1. By Type
12.6.2. By Treatment Type
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Muscle Wasting Disorders Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Type, 2017‒2031
13.2.1. Muscular Dystrophy
13.2.1.1. Duchenne Muscular Dystrophy (DMD)
13.2.1.2. Becker Muscular Dystrophy (BMD)
13.2.1.3. Myotonic Muscular Dystrophy
13.2.1.4. Congenital Muscular Dystrophy
13.2.1.5. Limb-Girdle Muscular Dystrophy
13.2.1.6. Others
13.2.2. Muscular Atrophy
13.2.2.1. Physiologic Atrophy
13.2.2.2. Pathologic Atrophy
13.2.2.3. Neurogenic Atrophy
13.3. Market Value Forecast By Treatment Type, 2017‒2031
13.3.1. Medications
13.3.2. Physical Therapy
13.3.2.1. Ultrasound Therapy
13.3.2.2. Electric Simulations
13.3.3. Nutritional Therapy
13.3.4. Surgery
13.3.5. Gene Therapy
13.3.6. Others
13.4. Market Value Forecast By End-user, 2017‒2031
13.4.1. Hospitals
13.4.2. Rehab Centers
13.4.3. Specialty Clinics
13.4.4. Others
13.5. Market Value Forecast By Country/Sub-region, 2017‒2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of LATAM
13.6. Market Attractiveness Analysis
13.6.1. By Type
13.6.2. By Treatment Type
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Muscle Wasting Disorders Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Type, 2017‒2031
14.2.1. Muscular Dystrophy
14.2.1.1. Duchenne Muscular Dystrophy (DMD)
14.2.1.2. Becker Muscular Dystrophy (BMD)
14.2.1.3. Myotonic Muscular Dystrophy
14.2.1.4. Congenital Muscular Dystrophy
14.2.1.5. Limb-Girdle Muscular Dystrophy
14.2.1.6. Others
14.2.2. Muscular Atrophy
14.2.2.1. Physiologic Atrophy
14.2.2.2. Pathologic Atrophy
14.2.2.3. Neurogenic Atrophy
14.3. Market Value Forecast By Treatment Type, 2017‒2031
14.3.1. Medications
14.3.2. Physical Therapy
14.3.2.1. Ultrasound Therapy
14.3.2.2. Electric Simulations
14.3.3. Nutritional Therapy
14.3.4. Surgery
14.3.5. Gene Therapy
14.3.6. Others
14.4. Market Value Forecast By End-user, 2017‒2031
14.4.1. Hospitals
14.4.2. Rehab Centers
14.4.3. Specialty Clinics
14.4.4. Others
14.5. Market Value Forecast By Country/Sub-region, 2017‒2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Type
14.6.2. By Treatment Type
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Biogen, Inc.
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Business Strategies
15.3.1.5. Recent Developments
15.3.2. F. Hoffmann-La Roche Ltd
15.3.2.1. Company Overview
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. Business Strategies
15.3.2.5. Recent Developments
15.3.3. Novartis AG
15.3.3.1. Company Overview
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. Business Strategies
15.3.3.5. Recent Developments
15.3.4. Ionis Pharmaceuticals, Inc.
15.3.4.1. Company Overview
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. Business Strategies
15.3.4.5. Recent Developments
15.3.5. Sarepta Therapeutics, Inc.
15.3.5.1. Company Overview
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. Business Strategies
15.3.5.5. Recent Developments
15.3.6. Nippon Shinyaku Co., Ltd. (NS Pharma, Inc.)
15.3.6.1. Company Overview
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. Business Strategies
15.3.6.5. Recent Developments
15.3.7. PTC Therapeutics, Inc.
15.3.7.1. Company Overview
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. Business Strategies
15.3.7.5. Recent Developments
15.3.8. Teva Pharmaceutical Industries Ltd.
15.3.8.1. Company Overview
15.3.8.2. Financial Overview
15.3.8.3. Product Portfolio
15.3.8.4. Business Strategies
15.3.8.5. Recent Developments
List of Tables
Table 01: Global Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 02: Global Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Muscular Dystrophy, 2017–2031
Table 03: Global Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Muscular Atrophy, 2017–2031
Table 04: Global Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 05: Global Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Physical Therapy, 2017–2031
Table 06: Global Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 07: Global Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 08: North America Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 09: North America Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 10: North America Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Muscular Dystrophy, 2017–2031
Table 11: North America Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Muscular Atrophy, 2017–2031
Table 12: North America Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 13: North America Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 14: North America Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 15: Europe Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 16: Europe Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 17: Europe Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Muscular Dystrophy, 2017–2031
Table 18: Europe Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Muscular Atrophy, 2017–2031
Table 19: Europe Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 20: Europe Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 21: Europe Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 22: Asia Pacific Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 23: Asia Pacific Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 24: Asia Pacific Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Muscular Dystrophy, 2017–2031
Table 25: Asia Pacific Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Muscular Atrophy, 2017–2031
Table 26: Asia Pacific Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 27: Asia Pacific Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 28: Asia Pacific Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 29: Latin America Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 30: Latin America Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 31: Latin America Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Muscular Dystrophy, 2017–2031
Table 32: Latin America Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Muscular Atrophy, 2017–2031
Table 33: Latin America Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 34: Latin America Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 35: Latin America Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 36: Middle East & Africa Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 37: Middle East & Africa Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 38: Middle East & Africa Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Muscular Dystrophy, 2017–2031
Table 39: Middle East & Africa Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Muscular Atrophy, 2017–2031
Table 40: Middle East & Africa Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 41: Middle East & Africa Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 42: Middle East & Africa Muscle Wasting Disorders Market Value (US$ Mn) Forecast, by End-user, 2017–2031
List of Figures
Figure 01: Global Muscle Wasting Disorders Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Muscle Wasting Disorders Market Value Share, by Type, 2022
Figure 03: Global Muscle Wasting Disorders Market Value Share, by Treatment Type, 2022
Figure 04: Global Muscle Wasting Disorders Market Value Share, by End-user, 2022
Figure 05: Global Muscle Wasting Disorders Market Value Share Analysis, by Type, 2022 and 2031
Figure 06: Global Muscle Wasting Disorders Market Attractiveness Analysis, by Type, 2023–2031
Figure 07: Global Muscle Wasting Disorders Market (US$ Mn), by Muscular Dystrophy, 2017–2031
Figure 08: Global Muscle Wasting Disorders Market (US$ Mn), by Muscular Atrophy, 2017–2031
Figure 09: Global Muscle Wasting Disorders Market Value Share Analysis, by Treatment Type, 2022 and 2031
Figure 10: Global Muscle Wasting Disorders Market Attractiveness Analysis, by Treatment Type, 2023–2031
Figure 11: Global Muscle Wasting Disorders Market (US$ Mn), by Medications, 2017–2031
Figure 12: Global Muscle Wasting Disorders Market (US$ Mn), by Physical Therapy, 2017–2031
Figure 13: Global Muscle Wasting Disorders Market (US$ Mn), by Nutritional Therapy, 2017–2031
Figure 14: Global Muscle Wasting Disorders Market (US$ Mn), by Surgery, 2017–2031
Figure 15: Global Muscle Wasting Disorders Market (US$ Mn), by Gene Therapy, 2017–2031
Figure 16: Global Muscle Wasting Disorders Market (US$ Mn), by Others, 2017–2031
Figure 17: Global Muscle Wasting Disorders Market Value Share Analysis, by End-user, 2022 and 2031
Figure 18: Global Muscle Wasting Disorders Market Attractiveness Analysis, by End-user, 2023–2031
Figure 19: Global Muscle Wasting Disorders Market (US$ Mn), by Hospitals, 2017–2031
Figure 20: Global Muscle Wasting Disorders Market (US$ Mn), by Rehab Centers, 2017–2031
Figure 21: Global Muscle Wasting Disorders Market (US$ Mn), by Specialty Clinics, 2017–2031
Figure 22: Global Muscle Wasting Disorders Market (US$ Mn), by Others, 2017–2031
Figure 23: Global Muscle Wasting Disorders Market Value Share Analysis, by Region, 2022 and 2031
Figure 24: Global Muscle Wasting Disorders Market Attractiveness Analysis, by Region, 2023–2031
Figure 25: North America Muscle Wasting Disorders Market Value (US$ Mn) Forecast, 2017–2031
Figure 26: North America Muscle Wasting Disorders Market Value Share Analysis, by Country, 2022 and 2031
Figure 27: North America Muscle Wasting Disorders Market Attractiveness Analysis, by Country, 2023–2031
Figure 28: North America Muscle Wasting Disorders Market Value Share Analysis, by Type, 2022 and 2031
Figure 29: North America Muscle Wasting Disorders Market Attractiveness Analysis, by Type, 2023–2031
Figure 30: North America Muscle Wasting Disorders Market Value Share Analysis, by Treatment Type, 2022 and 2031
Figure 31: North America Muscle Wasting Disorders Market Attractiveness Analysis, by Treatment Type, 2023–2031
Figure 32: North America Muscle Wasting Disorders Market Value Share Analysis, by End-user, 2022 and 2031
Figure 33: North America Muscle Wasting Disorders Market Attractiveness Analysis, by End-user, 2023–2031
Figure 34: Europe Muscle Wasting Disorders Market Value (US$ Mn) Forecast, 2017–2031
Figure 35: Europe Muscle Wasting Disorders Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 36: Europe Muscle Wasting Disorders Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 37: Europe Muscle Wasting Disorders Market Value Share Analysis, by Type, 2022 and 2031
Figure 38: Europe Muscle Wasting Disorders Market Attractiveness Analysis, by Type, 2023–2031
Figure 39: Europe Muscle Wasting Disorders Market Value Share Analysis, by Treatment Type, 2022 and 2031
Figure 40: Europe Muscle Wasting Disorders Market Attractiveness Analysis, by Treatment Type, 2023–2031
Figure 41: Europe Muscle Wasting Disorders Market Value Share Analysis, by End-user, 2022 and 2031
Figure 42: Europe Muscle Wasting Disorders Market Attractiveness Analysis, by End-user, 2023–2031
Figure 43: Asia Pacific Muscle Wasting Disorders Market Value (US$ Mn) Forecast, 2017–2031
Figure 44: Asia Pacific Muscle Wasting Disorders Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 45: Asia Pacific Muscle Wasting Disorders Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 46: Asia Pacific Muscle Wasting Disorders Market Value Share Analysis, by Type, 2022 and 2031
Figure 47: Asia Pacific Muscle Wasting Disorders Market Attractiveness Analysis, by Type, 2023–2031
Figure 48: Asia Pacific Muscle Wasting Disorders Market Value Share Analysis, by Treatment Type, 2022 and 2031
Figure 49: Asia Pacific Muscle Wasting Disorders Market Attractiveness Analysis, by Treatment Type, 2023–2031
Figure 50: Asia Pacific Muscle Wasting Disorders Market Value Share Analysis, by End-user, 2022 and 2031
Figure 51: Asia Pacific Muscle Wasting Disorders Market Attractiveness Analysis, by End-user, 2023–2031
Figure 52: Latin America Muscle Wasting Disorders Market Value (US$ Mn) Forecast, 2017–2031
Figure 53: Latin America Muscle Wasting Disorders Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 54: Latin America Muscle Wasting Disorders Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 55: Latin America Muscle Wasting Disorders Market Value Share Analysis, by Type, 2022 and 2031
Figure 56: Latin America Muscle Wasting Disorders Market Attractiveness Analysis, by Type, 2023–2031
Figure 57: Latin America Muscle Wasting Disorders Market Value Share Analysis, by Treatment Type, 2022 and 2031
Figure 58: Latin America Muscle Wasting Disorders Market Attractiveness Analysis, by Treatment Type, 2023–2031
Figure 59: Latin America Muscle Wasting Disorders Market Value Share Analysis, by End-user, 2022 and 2031
Figure 60: Latin America Muscle Wasting Disorders Market Attractiveness Analysis, by End-user, 2023–2031
Figure 61: Middle East & Africa Muscle Wasting Disorders Market Value (US$ Mn) Forecast, 2017–2031
Figure 62: Middle East & Africa Muscle Wasting Disorders Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 63: Middle East & Africa Muscle Wasting Disorders Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 64: Middle East & Africa Muscle Wasting Disorders Market Value Share Analysis, by Type, 2022 and 2031
Figure 65: Middle East & Africa Muscle Wasting Disorders Market Attractiveness Analysis, by Type, 2023–2031
Figure 66: Middle East & Africa Muscle Wasting Disorders Market Value Share Analysis, by Treatment Type, 2022 and 2031
Figure 67: Middle East & Africa Muscle Wasting Disorders Market Attractiveness Analysis, by Treatment Type, 2023–2031
Figure 68: Middle East & Africa Muscle Wasting Disorders Market Value Share Analysis, by End-user, 2022 and 2031
Figure 69: Middle East & Africa Muscle Wasting Disorders Market Attractiveness Analysis, by End-user, 2023–2031
Figure 70: Market Share Analysis, by Company (2022)
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Muscle Wasting Disorders Market
*86 figures and 60 tables includes